Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Size and Demand Forecast 2026–2030
Uncover key drivers, emerging technologies, and competitive movements shaping the primary progressive multiple sclerosis (ppms) treatment market from 2026–2035 with trusted insights from The Business Research Company
What are the forecasted starting (2026) and ending (2030) market sizes for the Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
The market for primary progressive multiple sclerosis (ppms) treatment has experienced substantial growth in recent times. This market is projected to expand from $1.16 billion in 2025 to $1.31 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 13.7%. Historically, this growth was influenced by factors such as the restricted availability of ppms treatment options, the common use of corticosteroids for managing symptoms, a general lack of patient awareness regarding ppms, an undeveloped infrastructure for hospital pharmacies, and the gradual uptake of immunosuppressants.
The primary progressive multiple sclerosis (ppms) treatment market size is expected to undergo rapid expansion in the coming years. This market is projected to reach $2.18 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. The anticipated growth during this period stems from the introduction of targeted monoclonal antibodies, increased research and development efforts in neurodegenerative disorders, the expansion of hospital and online pharmacy networks, a rise in regulatory approvals for novel therapeutics, and enhanced patient awareness and early diagnosis programs. Significant trends for the forecast period include the increasing adoption of monoclonal antibodies for ppms, a heightened focus on symptom management and quality of life, a growing preference for intravenous drug administration, the expansion of hospital and specialty pharmacy channels, and the development of new therapeutics and combination therapies.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp
What Drivers Are Supporting Technological Adoption In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
The primary progressive multiple sclerosis (PPMS) treatment market is anticipated to expand due to the increasing need for successful therapies. These successful therapies encompass medical interventions designed to alleviate symptoms, enhance patient results, or resolve a particular illness or condition. This escalating demand for efficacious treatments primarily stems from the rising occurrence of long-term and intricate health issues, necessitating ongoing care and advanced therapeutic methods to better patient well-being and life quality. Specifically, in primary progressive multiple sclerosis (PPMS), effective treatments contribute to slowing disease progression by addressing inflammation and safeguarding neurological function. This, in turn, leads to an improved long-term quality of life, a decrease in disability progression, and an enhanced capacity for patients to manage their daily routines with increased autonomy and steadiness. An illustrative example, cited in January 2024 by the American Society of Gene & Cell Therapy, a US organization focused on gene and cell therapy, revealed that the number of gene therapies undergoing Phase III clinical trials reached 33 Phase III gene therapy trials in 2023. This marked an increase of 10% compared to 2022, signifying the initial quarterly rise observed since the third quarter of 2022. Consequently, the increasing need for effective treatments is a key factor propelling the expansion of the primary progressive multiple sclerosis (PPMS) treatment market.
Which Segments Are Contributing To The Growth Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
The primary progressive multiple sclerosis (ppms) treatment market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab
2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide
3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone
4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone
What Trends Are Expected To Impact The Competitive Landscape Of The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
Companies operating in the primary progressive multiple sclerosis (PPMS) treatment market are concentrating on developing advanced formulations, such as monoclonal antibody drugs, to enhance the treatment of multiple sclerosis. Monoclonal antibody drugs aid in multiple sclerosis by targeting particular immune cells or proteins responsible for inflammation and nervous system damage, which in turn reduces disease activity and delays the advancement of symptoms. For instance, Roche Pharma India, an India-based pharmaceutical company, launched Ocrevus (ocrelizumab) in February 2024 as a monoclonal antibody drug specifically for treating multiple sclerosis (MS) in India. Ocrevus stands out as the first and sole approved disease-modifying therapy (DMT) in the country for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). The drug functions by targeting CD20-positive B cells, a type of immune cell implicated in the abnormal immune response observed in MS. It is administered via a twice-yearly intravenous infusion lasting only two hours, offering patients a more convenient and efficient treatment choice.
Who Are The Core Companies Influencing Trends In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market?
Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA
Access The Complete Report For Deeper Market Insights:
Which Regions Are Projected To Dominate The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market In The Coming Years?
North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24670&type=smp
Browse Through More Reports Similar to the Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market 2026, By The Business Research Company
Multiple Sclerosis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report
Atherosclerosis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report
Focal Segmental Glomerulosclerosis Drugs Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
